EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Negative allosteric modulator of the metabotropic glutamate receptor 7 ADX71743 increases wakefulness, reduces sleep, and alters stress-induced changes in the brain neurotransmitter levels

Mikhail Kalinichev iD, John A Gruner, Gunnar Flik, Mariette Heins, Hasnaa Haddouk, Isabelle Royer-Urios, Simon T Bate, Sonia Poli, Robert Lütjens

International Journal of Neuropsychopharmacology · 02.06.2026 · 29 (6)

DOI: 10.1093/ijnp/pyag025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 11.05.2026. Verfasst von Mikhail Kalinichev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Addex Therapeutics, Chemin des Mines 9, CH1202, Geneva, Switzerland. Hauptthemen laut MEDLINE: Receptors, Metabotropic Glutamate, Wakefulness, Sleep, Brain. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Addex Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Converging evidence suggests that metabotropic glutamate receptor 7 (mGlu7) contributes to sleep–wake regulation and stress reactivity. We used the selective negative allosteric modulator (NAM) ADX71743 to examine the role of mGlu7 in sleep–wake control and in basal and stress-evoked neurotransmitter release in freely moving rats.

Method

Rats were implanted with electrodes and telemetry devices to record electroencephalogram (EEG), neck muscle electromyogram (EMG), motor activity (MA), and body temperature (BT) at baseline and for 9 h after subcutaneous (sc) administration of ADX71743 (50, 100, or 150 mg/kg) or vehicle (50% cyclodextrin in water), given 2 h after lights on. In a separate cohort, rats were implanted with microdialysis probes in the prefrontal cortex (PFC) and ventral hippocampus (vHipp). Samples were collected at baseline, followed by sc ADX71743 (100 mg/kg) or vehicle and 10 min of light handling, 60 min later. Extracellular glutamate (Glu), GABA, glycine (Gly), serotonin (5-HT), norepinephrine (NE), and dopamine (DA) were quantified over the 180 min sampling period.

Results

ADX71743 increased wakefulness by up to 100% and reduced rapid eye-movement (REM) sleep by up to 100% and non-REM (NREM) sleep by up to 75% (all P < .05), with comparable effects across doses. ADX71743 also delayed NREM and REM sleep onset by nearly 2-fold (P < .05) for 2 h after dosing, without altering MA or BT. Basal neurotransmitter concentrations were unchanged. However, ADX71743 attenuated stress-related changes in GABA and 5-HT, maintaining higher levels in the vHipp than in vehicle-treated controls. Stress-evoked NE and DA increases tended to be greater after ADX71743 than after vehicle. Neither treatment nor stress markedly affected Glu or Gly in the PFC or vHipp.

Conclusions

These findings support an important role for mGlu7 in regulating sleep and wakefulness. The ADX71743-associated maintenance of higher vHipp 5-HT and GABA levels after stress may contribute to reduced stress- and anxiety-like reactivity produced by mGlu7 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Metabotropic GlutamateWakefulnessSleepBrainStress, PsychologicalNeurotransmitter AgentsIsoxazolesAnimalsMaleRats, Sprague-DawleyRatsDose-Response Relationship, DrugAllosteric RegulationBody TemperatureElectroencephalographyMotor ActivityGlutamic AcidPyridones

Stichwörter der Autor:innen

ADX71743GABAmGlu7negative allosteric modulatorserotoninsleep–wakefulness

Substanzen

Receptors, Metabotropic Glutamatemetabotropic glutamate receptor 7Neurotransmitter Agents6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo(4,5-c)pyridin-4(5H)-oneIsoxazolesGlutamic AcidPyridones

Autor:innen und Institutionen

  • Addex Therapeutics, Chemin des Mines 9, CH1202, Geneva, Switzerland.
  • Melior Discovery, 860 Springdale Drive, Exton, PA, 19341, United States.
  • Brains On-Line, B.V., PO Box 4030, 9701, Groningen EA, The Netherlands.
  • HLS, Huntingdon, Cambridgeshire, PE28 4HS, United Kingdom.

ORCID-Profile: Mikhail Kalinichev

Förderung

  • Addex Therapeutics

Zitieren

APA

Kalinichev, M., Gruner, J. A., Flik, G., Heins, M., Haddouk, H., Royer-Urios, I., Bate, S. T., Poli, S., & Lütjens, R. (2026). Negative allosteric modulator of the metabotropic glutamate receptor 7 ADX71743 increases wakefulness, reduces sleep, and alters stress-induced changes in the brain neurotransmitter levels. International Journal of Neuropsychopharmacology, 29(6). https://doi.org/10.1093/ijnp/pyag025

Vancouver

Kalinichev M, Gruner JA, Flik G, Heins M, Haddouk H, Royer-Urios I, et al. Negative allosteric modulator of the metabotropic glutamate receptor 7 ADX71743 increases wakefulness, reduces sleep, and alters stress-induced changes in the brain neurotransmitter levels. International Journal of Neuropsychopharmacology. 2026;29(6). doi:10.1093/ijnp/pyag025

BibTeX
@article{Kalinichev2026,
  author = {Kalinichev, Mikhail and Gruner, John A and Flik, Gunnar and Heins, Mariette and Haddouk, Hasnaa and Royer-Urios, Isabelle and Bate, Simon T and Poli, Sonia and Lütjens, Robert},
  title = {Negative allosteric modulator of the metabotropic glutamate receptor 7 ADX71743 increases wakefulness, reduces sleep, and alters stress-induced changes in the brain neurotransmitter levels},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2026},
  volume = {29},
  number = {6},
  doi = {10.1093/ijnp/pyag025}
}
Kostenlos starten →